Nucleai and Sirona Dx to Provide New Proteomics Solution for Pharma Companies
Nucleai and Sirona Dx have formed a partnership to deliver an end‑to‑end spatial proteomics solution for pharmaceutical and biotech companies. The joint offering unifies assay design, high‑quality imaging, and AI‑driven analytics to turn complex tissue data into actionable biological insights. By covering the full workflow—from assay validation to biomarker discovery—the collaboration targets drug‑development programs in immunology, neuroscience and oncology. Executives say the integrated path will improve biomarker decisions and raise the probability of clinical success.
Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study
Boehringer Ingelheim and Zai Lab have launched a Phase Ib/II trial that pairs Boehringer’s DLL3‑directed T‑cell engager obrixtamig with Zai Lab’s DLL3‑targeting ADC zoci. The study will evaluate safety, tolerability and early efficacy in patients with extensive‑stage small‑cell lung cancer and other neuroendocrine...
EU Sees 2025 Pharma Export Uptick Amid Competitiveness Concerns
EU pharmaceutical exports surged 16% in 2025, reaching €366.2 bn (≈$429 bn) and generating a record trade surplus of €220.5 bn (≈$257 bn). The United States remained the top destination, accounting for 44% of shipments – roughly €160.6 bn (≈$188 bn). Tariff pressures, including a 15%...
Pharma 5.0, Sustainability & Security: PHARMAP 2026 Brings Pharma’s Future Into Focus
PHARMAP Congress 2026 will convene pharma leaders in Amsterdam on April 20‑21 to address digital transformation, sustainability, and security. The event highlights the shift from Pharma 4.0 to Pharma 5.0, focusing on AI‑human collaboration and Quality 5.0’s integrative approach. Speakers will showcase circular packaging...
AbbVie Bets on Chinese Biopharma’s Pain Pipeline in $745m Bid
AbbVie has struck a deal worth up to $745 million with Chinese biopharma Haisco, securing development, manufacturing and commercialization rights to several early‑stage pain‑relief compounds outside China, Hong Kong and Macau. The agreement includes a $30 million upfront payment and up to $715 million...
Telix and Regeneron Sign $4.3bn Deal to Co-Develop Radiopharmaceutical Therapies
Telix and Regeneron Pharmaceuticals have signed a partnership valued at up to $4.3 billion to co‑develop radiopharmaceutical therapies for solid tumours. Regeneron will pay $40 million upfront for access to Telix’s manufacturing platform and can expand to four additional programmes, while Telix...
BMS and Oxford BioTherapeutics Join Forces in TCE Discovery Pact
Bristol Myers Squibb has entered a discovery partnership with Oxford BioTherapeutics to develop T‑cell engager (TCE) therapies for solid tumours. BMS will pay an undisclosed upfront fee to access OBT’s OGAP‑Verify platform, while OBT will design and deliver pre‑clinical candidates....
Emerging Therapies Bring Hope for Frail HNSCC Patients Unfit for Standard Treatment
Head and neck squamous cell carcinoma (HNSCC) cases are projected to rise to 273,000 by 2034, with frail and elderly patients expected to comprise 44% of the market. Standard curative regimens are often intolerable for this group, creating a sizable...
Advancing Single-Cell Transcriptomics Into the Mainstream of Biomedical Research
Single‑cell transcriptomics is transitioning from a niche method to a core biomedical tool, offering cell‑level gene‑expression detail that fuels advances in cancer, immunology and cell‑therapy research. Manual library‑preparation steps limit throughput to about 24 samples per day, creating bottlenecks for...
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development is shifting toward precision immunotherapies, with biomarkers driving patient selection and trial efficiency. Experts at a Caidya webinar highlighted two trends: novel combination regimens and early integration of biomarker strategies, including companion diagnostics. Early biomarker adoption can...
Gan & Lee and JW Pharmaceutical Agree on Bofanglutide Commercialisation
Gan & Lee Pharmaceuticals has signed an exclusive licence with JW Pharmaceutical to develop and commercialise the GLP‑1RA bofonaglutide in South Korea. JW will receive a $5 million upfront payment and up to $76.1 million in milestones, bringing total potential value to...
EverSea Medicines to Acquire Hasten Biopharmaceuticals
Everest Medicines, through its Singapore subsidiary EverSea Medicines, signed a share purchase agreement to acquire Hasten Biopharmaceuticals (Asia) for a total consideration of $250 million, payable in three instalments. The deal brings trademark, commercial and marketing authorisation holder (MAH) rights for...
FDA Seeks Permanent Future for Rare Pediatric Priority Review Vouchers
The FDA announced plans to permanently authorize the rare pediatric disease priority‑review voucher (PRV) program as part of its $7.2 billion FY 2027 budget request. The initiative ends the cycle of four‑year reauthorizations that left the program in limbo after its 2024...
Shionogi Secures $482m BARDA Contract to Tackle AMR Crisis
Japanese pharmaceutical firm Shionogi has secured a BARDA contract worth up to $482 million to build a U.S.-based manufacturing facility for its injectable antibiotic Fetroja (cefiderocol). The agreement provides $119 million upfront and up to $363 million over several years, enabling production aimed...
RoosterBio and MineBio Team up to Expand MSC Solutions Access in China
RoosterBio has signed an exclusive distribution agreement with MineBio Life Sciences to bring its research‑grade and cGMP‑grade mesenchymal stem cell (MSC) and exosome bioprocessing media to China. MineBio has already secured import clearance, allowing rapid fulfillment of orders for both...
